LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial

LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 33; p. S1406
Main Authors: Haanen, J.B.A.G., Rohaan, M., Borch, T.H., van den Berg, J.H., Met, Ö., Foppen, M. Geukes, Granhøj, J. Stoltenborg, Nuijen, B., Nijenhuis, C., Beijnen, J.H., Jedema, I., van Zon, M., Noringriis, I. Mansfield, Kessels, R., Wilgenhof, S., van Thienen, H.V., Lalezari, F., van Akkooi, A.C.J., Donia, M., Svane, I-M.
Format: Journal Article
Language:English
Published: 01-09-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1016/j.annonc.2022.08.036